Exton-Based Pharmaceutical Company Gets Green Light from FDA for Ulcer Medicine

By

Clayton Pharmaceutical
Image via Absorption Systems.
Sid Bhoopathy, president and CEO of Clayton Pharmaceuticals.

Exton-based Clayton Pharmaceuticals has received FDA approval for a new generic ulcer medication that it is developing through a partnership with Florida-based VistaPharm and Neuheit Pharma Technologies of India, writes John George for the Philadelphia Business Journal. 

With the approval of his sucralfate oral suspension product, Sid Bhoopathy, CEO of Clayton Pharmaceuticals, hopes that access to more affordable, life-saving generic drugs will increase. 

“This is a proud moment for Clayton and our partners,” said Bhoopathy. “We are buoyed by the approval of this product, and ready to solve the bioequivalence challenges for the next set of complex products.” 

Two other Exton-based companies, Absorption Systems and CellPort Software, helped with testing and analytics support for the development. 

Bhoopathy is also the senior vice president and head of U.S. laboratory services at Absorption Systems. 

Last year, sales of the sucralfate oral suspension product totaled $188.5 million. Meanwhile, $157.9 million of that was for the generic version of the drug.

Read more about Clayton Pharmaceuticals in the Philadelphia Business Journal. 

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo